NBRV News and Press, Nabriva Therapeutics plc From 06/23/20

CymaBay Posts Positive Seladelpar Data for Bile Duct Disorder CymaBay Therapeutics ( CBAY ) reported upbeat data for its open label Phase 2 study of seladelpar for treating patients suffering from primary biliary cholangitis. Seladelpar is a potent and selective peroxisome proliferator-a...

Nabriva Therapeutics (NASDAQ: NBRV ) has received a CRL from the FDA in response to its refiled marketing application seeking approval of Contepo (fosfomycin) for the treatment of complicated urinary tract infections, including pyelonephritis (urinary tract infection that has traveled to t...

DUBLIN, Ireland, June 19, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it received a Complete Response Lett...

3 Penny Stocks To Watch Penny stocks are back in focus this week. After one of the most wilds weeks last week, it will be interesting to see what happens next. The sheer amount of new traders looking for penny stocks to buy is a sign of the times. There’s volatility in the stock ...

Gainers: Cemtrex (NASDAQ: CETX )  +209% . More news on: Cemtrex, Inc., Digital Ally, Inc., Allied Esports Entertainment Inc., Stocks on the move, , Read more ...

Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...

Nabriva Therapeutics (NASDAQ: NBRV ) inks an agreement with several institutional investors for the direct sale of 41,445,373 ordinary shares, each with an accompanying two-year warrant to purchase one ordinary share at $0.792, at a combined price of $0.91686. More news on: Nabriva Thera...

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has enter...

3 Penny Stocks To Watch Right Now Putting your money into penny stocks can be exciting and scary at the same time. Exciting because penny stocks offer high potential for large gains. Scary because these high flying penny stocks are also highly risky too. But if you can handle a little bit of...

If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe   CHMP opinion supported by robust safety and efficacy data from two global pivotal Phase 3 trials of XENLETA ...